{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Syndax Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"SNDX"},"Address":{"label":"Address","value":"35 GATEHOUSE DRIVE,BUILDING D, FLOOR 3, WALTHAM, Massachusetts, 02451, United States"},"Phone":{"label":"Phone","value":"+1 781 419-1400"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.syndax.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Catherine Madigan","title":"Chief Medical Officer"},{"name":"Michael A. Metzger","title":"Chief Executive Officer & Director"},{"name":"Neil Gallagher","title":"President, Head-Research & Development"},{"name":"Peter Ordentlich","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}